CCL28

Across TCGA pan-cancer cohorts, CCL28 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCL28 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CCL28 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCL28 expression acts as an unfavorable survival marker.

BLCA, LUSC, and LUAD are the cancer types where CCL28 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	36	view →
LUSC	OS	Median	All	0.138	0.818	.003	9	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCL28–BLCA (OS)

Open the BLCA breakdown →